HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, March 13 (HealthDay News) -- In patients with diabetic cardiomyopathy, treatment with angiotensin type 1 receptor antagonists may help prevent cardiac fibrosis and failure, according to the results of an animal study published in the March issue of Diabetes.
Dirk Westermann, M.D., of the Charite Universitatsmedizin Berlin in Germany, and colleagues injected mice with streptozotocin, which induced diabetes and diabetic cardiomyopathy. They studied the effects of the angiotensin type 1 receptor antagonist irbesartan.
The researchers found that irbesartan improved the dysregulation of the cardiac extracellular matrix, normalized matrix metalloproteinase activity, reduced cardiac transforming growth factor-beta and interleukin 1-beta levels, and decreased cardiac fibrosis. Despite the presence of severe hyperglycemia, these changes were associated with improved left ventricular function, the report indicates.
"Since it is possible that sub-therapeutic insulin administration to streptozotocin-injected mice may be the better model for human diabetic cardiomyopathy, the influence of insulin treatment on the effect of angiotensin receptor blockers has to be evaluated," the authors conclude.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.